Bicara Therapeutics BCAX Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's stock options excluded as their inclusion would be anti-dilutive (in shares)?
- Bicara Therapeutics (BCAX) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 8.3M in Q4 2025.
- What does stock options excluded as their inclusion would be anti-dilutive (in shares) mean?
- This represents the number of potential common shares from stock options, warrants, or convertible instruments that are excluded from the diluted earnings per share calculation because their inclusion would increase earnings per share or decrease the loss per share. These securities are considered anti-dilutive under current market conditions. Tracking this provides insight into potential future dilution if the company's share price or profitability improves.